Trochlear dysplasia is a developmental condition characterised by an abnormally flat or dome shaped trochlea and is an important contributing factor to patellofemoral instability and recurrent patellar dislocation. We prospectively studied a cohort of 54 consecutive patients (59 knees) with patellofemoral instability secondary to trochlear dysplasia, treated with a trochleoplasty by a single surgeon over a 5 year period. Patients were recruited from the senior author's specialist knee clinic and pre-operatively, multiple patient-centred scores were recorded. After the trochleoplasty, these were repeated along with a patient satisfaction questionnaire. Of the 54 patients and 59 knees operated, 39 of the patients (44 knees) were female and 15 (15 knees) male and 40 patients (42 knees) had follow-up of 12 months or more. Their mean age at surgery was 21 years and 6 months and mean length of follow up 2 years. One patient was unable to attend for follow up due to the development of a pelvic Ewings sarcoma. A statistically significant improvement in outcomes was demonstrated when the pre and post-operative scores were compared (mean scores of Oxford 26 to 19, WOMAC 23 to 17, IKDC 54 to 72, Kujala 62 to 76, Lysholm 57 to 78, p values <0.001 for all scores). 93% (50 patients) were satisfied with the outcome of their procedure. We conclude that in the short and medium term, the results of trochleoplasty are encouraging in this challenging group of patients.
At the end of the follow up period, 11 of the 70 acetabular components (polyethylene liner or the acetabular shell) had been revised. The cumulative survival was 94.0% (95% confidence interval 88.4–99.7) with revision of the metal shell as the end point, and 84.0% (95% confidence interval 74.5–93.5) with revision surgery of the acetabular shell or liner due to any reason as an end point. Radiologically, 4 patients require acetabular revision and 22 patients had femoral osteolysis in gruen zone 7, indicative of polyethylene failure. This gave a combined revision, impending revision and zone 7 osteolysis cumulative survival of 55.3% (95% confidence interval 40.6–70.0).
The National Institute for Clinical Excellence (NICE) was set up to provide patients, health professionals and the public with authoritative, robust and reliable guidance on current “best practice”. To determine how useful for NICE guidelines for Selection of Prostheses for Primary Total Hip Replacement were to patients who were undergoing total hip replacement (THR) and the health professionals who were looking after them. We surveyed 100 patients, 50 Orthopaedic Surgeons, 40 Orthopaedic nurses and posted a questionnaire to GPs, to which 79 replied (56% response rate). 19% of patients had heard of NICE but only 2% were aware of the existence of NICE guidelines on THR and 1% found them useful. Almost all orthopaedic surgeons had heard of NICE and their guidelines for THR, with 74% knowing what the guidelines actually stated but only 14% finding them useful. 78% of surgeons believed that their preferred hip replacement conformed to NICE guidelines, 2% knew that they did not conform and 20% did not know. 27% of general practitioners knew of the guidelines, but only 5% knew what they actually stated and 1% found them useful in their practice. Most nursing staff working in orthopaedic areas had heard of NICE (83%). 43% knew of the NICE guidelines but only 13% knew the actual guidelines and % found them useful. NICE has failed to communicate its guidelines to both patients and the public. None of the groups found the guidelines useful. NICE has failed to fulfil its mission statement and may instead have other motives, such as empowering centralised regulation of healthcare in the NHS.
The National Institute for Clinical Excellence (NICE) was set up in the UK ‘to provide patients, health professionals and the public with authoritative, robust and reliable guidance on current best practice. In March 2000, NICE provided national guidelines for the selection of prostheses for total hip replacement.